Showing results (181-190 of 199) with videos related to
Sort By:
Pageof 20
Cancer Discovery|December 5, 2013
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancerFlorian Malchers, Felix Dietlein, Jakob Schöttle, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 24, 2015
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer PatientsKatharina König, Martin Peifer, Jana Fassunke, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR InhibitorsSandra Ortiz-Cuaran, Matthias Scheffler, Dennis Plenker, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2016
Clinicopathological Characteristics of RET Rearranged Lung Cancer in European PatientsSebastian Michels, Andreas Hans Scheel, Matthias Scheffler, et al.European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterationsMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2020
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of ImmunotherapyAnna Kron, Matthias Scheffler, Carina Heydt, et al.Nature Communications|November 9, 2018
Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 13, 2019
Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical TrialSebastian Michels, Bartomeu Massutí, Hans-Ulrich Schildhaus, et al.Clinical Lung Cancer|December 17, 2023
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung CancerMariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysMatthias Scheffler, Michaela A Ihle, Rebecca Hein, et al.Pageof 20